FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used in treatment of cancer. Pharmaceutical composition according to the invention contains a BRAF inhibitor vemurafenib and a tubulin inhibitor which is a compound of formula 17ya or 12da
Methods of the invention involve administration of the composition.
EFFECT: use of inventions enables suppressing growth of tumours by synergetic action of the combination, reducing the number of side effects.
12 cl, 17 tbl, 28 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| COMBINED THERAPY PAC-1 | 2016 |
|
RU2720509C2 |
| APILIMOD COMPOSITION AND METHODS OF USING IT IN TREATING MELANOMA | 2015 |
|
RU2731908C2 |
| METHOD FOR ADJUVANT THERAPY OF CANCER | 2013 |
|
RU2640180C2 |
| APILIMOD COMPOSITIONS AND METHODS OF USING THEM IN TREATING COLORECTAL CANCER | 2015 |
|
RU2739992C2 |
| BRAF KINASE INHIBITOR N-(3-(5-(4-CHLOROPHENYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-CARBONIL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE | 2018 |
|
RU2687107C1 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
| NEW METHYLQUINAZOLINONE DERIVATIVES | 2020 |
|
RU2802968C1 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| TREATING MALIGNANT TUMORS USING COMBINATIONS OF ERK AND RAF INHIBITORS | 2014 |
|
RU2722784C2 |
